Ives, Leo/Roche, Sterling patent extension requests
Executive Summary
Ives seeking two-year extension to Dec. 31, 1993 for Sectral (acebutolol HCl) caps, which would give the antihypertensive a nine-year monopoly; Leo/Roche requesting two-year extension to May 18, 1995 for Coactin (amdinocillin), to provide 10-1/2 years of patented marketing of the injectable antibiotic; Sterling seeking two-year extension for Tornalate (bitolterol mesylate), to give the metered-dose bronchodilator inhaler a 13-year monopoly. Three applications fall under the patent extension law's provision limiting extensions to two years for drugs whose clinicals began before enactment but were approved after enactment; FDA cleared the drugs in late December.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.